These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23116035)

  • 1. [Silodosin. From research to clinical application: the activity, safety and long-term effectiveness].
    Russo A; Hedlund P; Montorsi F
    Urologiia; 2012; (4):104-6, 108-9. PubMed ID: 23116035
    [No Abstract]   [Full Text] [Related]  

  • 2. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.
    Hussar DA
    J Am Pharm Assoc (2003); 2009; 49(2):347-50. PubMed ID: 19289354
    [No Abstract]   [Full Text] [Related]  

  • 5. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
    Lepor H; Hill LA
    Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profile of silodosin (URIEF Cap. 2 mg, 4 mg)].
    Kobayashi M; Shimizu T
    Nihon Yakurigaku Zasshi; 2006 Oct; 128(4):259-68. PubMed ID: 17038792
    [No Abstract]   [Full Text] [Related]  

  • 7. KMD 3213: KAD 3213, silodosin.
    Drugs R D; 2004; 5(1):50-1. PubMed ID: 14725494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough treatment for prostate enlargement.
    Johns Hopkins Med Lett Health After 50; 2003 Apr; 15(2):3, 7. PubMed ID: 12712965
    [No Abstract]   [Full Text] [Related]  

  • 9. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
    Homma Y; Kawabe K; Takeda M; Yoshida M
    Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?
    Morgia G
    Eur Urol; 2011 Mar; 59(3):353-5; discussion 355. PubMed ID: 21130562
    [No Abstract]   [Full Text] [Related]  

  • 11. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
    Masuda M; Jinza S; Masuko H; Asakura T; Hashiba T
    Hinyokika Kiyo; 2012 Dec; 58(12):671-8. PubMed ID: 23328162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment.
    Lowe FC
    Urology; 2009 Dec; 74(6):1323; author reply 1323-4. PubMed ID: 19962535
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of apha-blockaders in the treatment of prostatism].
    Penders L; Bouffioux C
    Acta Urol Belg; 1983; 51(4):518-31. PubMed ID: 6196958
    [No Abstract]   [Full Text] [Related]  

  • 16. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Using of alpha1-adrenoreceptor blockers in urologic practice].
    Shaplygin LV
    Voen Med Zh; 2007 Jul; 328(7):40-7. PubMed ID: 17902344
    [No Abstract]   [Full Text] [Related]  

  • 18. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I've been diagnosed with chronic prostatitis. What can I do for my frequent nighttime urination?
    Johns Hopkins Med Lett Health After 50; 2011 Oct; 23(8):7. PubMed ID: 22059259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.